ROIV earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -77.58. Updated 2026-07-23.
Roivant Sciences (ROIV) Research Hub
Roivant Sciences (ROIV) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 40.82 USD (-2.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -77.58, market cap 24.96B. This hub links to the full technical, earnings and options research available for ROIV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 40.82 USD (-2.37%) |
| 52-week range | 29.79 USD – 42.5 USD |
| Trend regime | Range |
| 14-day RSI | 64.4 (Bullish) |
| Trailing P/E | -77.58 |
| Market cap | 24.96B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ROIV
Covered Call on ROIV: how it works, illustrative setup around the real 40.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ROIV: how it works, illustrative setup around the real 40.82 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ROIV: how it works, illustrative setup around the real 40.82 USD price, max profit/loss, breakeven and when to use it. Educational.
ROIV technical analysis: range, last 40.82 USD, RSI 64.4, 52w range 29.79 USD–42.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ROIV in?
Roivant Sciences (ROIV) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is ROIV in an uptrend or downtrend?
As of 2026-09-11, ROIV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ROIV's trailing P/E ratio?
ROIV's trailing P/E is -77.58, with a market cap of 24.96B. See the earnings research page for full valuation detail.
When does ROIV next report earnings?
ROIV is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.33 USD.